Multifaceted approaches are needed to limit carbapenem-resistant Enterobacteriaceae (CRE) infections, including Klebsiella pneumoniae, which have emerged as a worldwide public health problem. These multidrug- resistant organisms are associated with high morbidity and mortality that often exceeds 50%, as highly effective and non-toxic treatment regimens are lacking. While intestinal colonization with CREs has been proposed as a potential risk factor for infections during CRE outbreaks, its actual contribution to infection remains incompletely understood. Moreover, there is a fundamental gap in knowledge on how these antibiotic resistant organisms transition from colonization to infection within affected hosts. The long-term goal of this application is to elucidate at the bacterial genome level how CRE infections emerge and spread. Understanding these processes is critical to developing intervention and real-time clinical monitoring approaches to limit the impac of CRE infections at an individual and population level. We will focus our study on patients after liver transplantation who are at very high risk for CRE infections and adverse outcomes. Our central hypothesis is that the intestine provides a microenvironment in which CRE can expand and adapt with small genetic variations and subsequently lead to infections. To address these questions we propose to establish a cohort study of adult patients undergoing liver transplant, and track CREs within affected patients and across the hospital. In this prospective cohort we will enroll 300 patients pre-transplant, collect stool samples to ascertain intestinal colonization pre- and repeatedly post-transplant, and assess patients for CRE infections over a 6-month period. Our study design will allow us to execute the following Aims: 1) Define the rate and role of colonization on CRE infection in liver transplant patients; 2) Evaluate the within-host evolutio from CRE colonization to infection; and 3) Investigate the spread of CRE between liver transplant and other patient populations in the hospital.
In Aim 1 we will test the contribution of CRE colonization to infection and characterize outcomes using Kaplan-Meier survival analyses and a Cox proportional hazard model.
In Aim 2 we will apply 16S and whole-genome sequencing to answer whether CRE colonization dominance develops prior to infection and how modifiable risk factors (e.g. certain antibiotics) relate to these adaptations. We will also define the clonal diversity of colonizing CRE and assess whether infectious isolates arise from dominant colonizing clones or acquire novel virulence traits.
In Aim 3 we will assess the within-hospital evolution and spread of CRE infections by extending whole-genome sequence analyses to infections that occurred in non- liver transplant patients. Our multidisciplinary approach is innovative in its combination of high-resolution genomics with detailed epidemiological investigations to monitor the evolution of CRE infections in real time. This research is significant with direct translational impact in establishing a framework to track the emergence of multi-drug resistant Enterobacteriaceae and to ultimately devise novel containment strategies for CREs.

Public Health Relevance

Carbapenem-resistant Enterobacteriaceae (CRE) infections are posing an urgent threat to healthcare. Patients after liver transplantation are disproportionally affected, with a >50% risk of fatal outcomes in cases of infection. Here we present a comprehensive approach to study the contribution of CRE colonization to infection at the pathogen genome level in a cohort of patients undergoing liver transplant. Moreover, we will characterize the micro-evolutionary changes underlying the transition to infections. The implementation of this project can be expected to yield real-time surveillance tools and to stimulate novel preventive approaches to limit the life- threatening impact of CRE infections.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI116939-01
Application #
8863907
Study Section
Clinical Research and Field Studies of Infectious Diseases Study Section (CRFS)
Program Officer
Huntley, Clayton C
Project Start
2015-01-14
Project End
2019-12-31
Budget Start
2015-01-14
Budget End
2015-12-31
Support Year
1
Fiscal Year
2015
Total Cost
$408,093
Indirect Cost
$149,285
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Mehta, Monica; Uhlemann, Anne-Catrin (2018) Beware of broad-spectrum generalizations: ceftazidime-avibactam compared to meropenem for the treatment of gram-negative pneumonia. J Emerg Crit Care Med 2:
Macesic, Nenad; Gomez-Simmonds, Angela; Sullivan, Sean B et al. (2018) Genomic Surveillance Reveals Diversity of Multidrug-Resistant Organism Colonization and Infection: A Prospective Cohort Study in Liver Transplant Recipients. Clin Infect Dis 67:905-912
Gomez-Simmonds, Angela; Annavajhala, Medini K; Wang, Zheng et al. (2018) Genomic and Geographic Context for the Evolution of High-Risk Carbapenem-Resistant Enterobacter cloacae Complex Clones ST171 and ST78. MBio 9:
Freedberg, Daniel E; Zhou, Margaret J; Cohen, Margot E et al. (2018) Pathogen colonization of the gastrointestinal microbiome at intensive care unit admission and risk for subsequent death or infection. Intensive Care Med :
Gomez-Simmonds, Angela; Stump, Stephania; Giddins, Marla J et al. (2018) Clonal Background, Resistance Gene Profile, and Porin Gene Mutations Modulate In Vitro Susceptibility to Imipenem-Relebactam in Diverse Enterobacteriaceae. Antimicrob Agents Chemother 62:
Giddins, Marla J; Macesic, Nenad; Annavajhala, Medini K et al. (2018) Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in blaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates. Antimicrob Agents Chemother 62:
Cheng, Lucy; Nelson, Brian C; Mehta, Monica et al. (2017) Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC ?-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother 61:
McConville, Thomas Howe; Sullivan, Sean Berger; Gomez-Simmonds, Angela et al. (2017) Carbapenem-resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study. PLoS One 12:e0186195
Macesic, Nenad; Nelson, Brian; Uhlemann, Anne-Catrin (2017) Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: De Novo or Drug Exposure? Clin Infect Dis 65:702-703
Gomez-Simmonds, Angela; Uhlemann, Anne-Catrin (2017) Clinical Implications of Genomic Adaptation and Evolution of Carbapenem-Resistant Klebsiella pneumoniae. J Infect Dis 215:S18-S27

Showing the most recent 10 out of 16 publications